Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. O'Reilly
    O'Reilly
  5. Rosenberg
    Rosenberg
  6. Paik
    Paik
  7. Saltz
    Saltz
  8. Scher
    Scher
  9. Yaeger
    Yaeger
  10. Hudis
    Hudis

Groups

  1. Department of Medicine (1264)
  2. Solid Tumor Oncology Division (1162)
  3. Gastrointestinal Oncology Service (289)
  4. Genitourinary Oncology Service (275)
  5. Thoracic Oncology (254)
  6. GSK Faculty (174)
  7. Hematologic Malignancies, Division of (150)
  8. Survivorship Research (150)
  9. Breast Medicine Service (140)
  10. Center for Pancreatic Cancer Research (119)
Search Within
  1. "Annals of Oncology"
Formats
  1. Meeting Abstract (1101)
  2. Journal Article (355)
  3. Guidelines (17)
  4. Review (14)
  5. Editorial (12)
  6. Conference Paper (8)
  7. Correspondence (2)
  8. Research Letter (1)
Groups
  1. Department of Medicine (1264)
  2. Solid Tumor Oncology Division (1162)
  3. Gastrointestinal Oncology Service (289)
  4. Genitourinary Oncology Service (275)
  5. Thoracic Oncology (254)
  6. GSK Faculty (174)

More Groups

People
  1. Alexander Drilon (84)
  2. Robert Motzer (73)
  3. Ghassan Abou-Alfa (50)
  4. Matthew Hellmann (49)
  5. Eileen O'Reilly (44)
  6. Jonathan Rosenberg (38)

More People

Years
  1. 2024 (5)
  2. 2023 (154)
  3. 2022 (158)
  4. 2021 (148)
  5. 2020 (152)
  6. 2019 (163)

More Years

Publications
  1. Annals of Oncology (1510)

Results (1510)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis
    Journal Article

    Piulats, J. M.; Watkins, C.; Costa-García, M.; del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J. C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
    Journal Article

    Saura, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; Iwata, H.; Tsurutani, J.; Sohn, J.; Mathias, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors
    Journal Article

    Lewis, K. D.; Peris, K.; Sekulic, A.; Stratigos, A. J.; Dunn, L.; Eroglu, Z.; Chang, A. L. S.; Migden, M. R.; Yoo, S. Y.; Mohan, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    Guidelines

    Loibl, S.; André, F.; Bachelot, T.; Barrios, C. H.; Bergh, J.; Burstein, H. J.; Cardoso, M. J.; Carey, L. A.; Dawood, S.; Del Mastro, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • POSing the question: MARIPOSA-2, do the ends justify the means?
    Editorial

    Chen, M. F.; Piotrowska, Z.; Yu, H. A.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
    Meeting Abstract

    Chou, H. I.; Lu, L.; Chung, C. T.; Chan, J. S. K.; Chan, R. N. C.; Lee, Y. H. A.; Dee, E. C.; Ng, K.; Pui, H. H. H.; Lee, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Armstrong, A. J.; Pook, D. W.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save